SBRT联合免疫治疗的机制及研究进展

近年来,大量临床前和临床研究表明,SBRT除直接杀伤肿瘤细胞外,还能导致肿瘤细胞免疫原性死亡,释放大量肿瘤相关抗原(TAA)及危险相关模式分子(DAMPs)形成肿瘤原位疫苗。通过激活的抗原提呈细胞交叉致敏引流淋巴结内的CD8(+) T细胞。SBRT能介导肿瘤局部和全身系统性的抗肿瘤免疫反应,与免疫治疗结合,还可以引发远位效应。SBRT同时能改善肿瘤免疫抑制微环境,增加肿瘤对免疫治疗的敏感性。本文对SBRT联合肿瘤免疫治疗的协同作用机制的研究进展进行综述。

Research advances in mechanisms for combination therapy with stereotactic body radiation therapy and immunotherapy

In recent years, a large number of pre-clinical and clinical investigations have indicated that stereotactic body radiation therapy (SBRT) can not only kill cancer cells directly,but also induce the immunogenic death of cancer cells through releasing numerous tumor-associated antigens and damage-associated molecular patterns to form in situ tumor vaccine. CD8(+) T cells in lymph nodes are cross-sensitized by activated antigen-presenting cells. SBRT initiates local and systemic anti-tumor immune response. Moreover, SBRT can induce the abscopal effect if combined with immunotherapy. In addition, SBRT improves the microenvironment for tumor immunosuppression and enhances the sensitivity of tumors to immunotherapy. This article reviews the research advances in the synergistic mechanisms for combination therapy with SBRT and immunotherapy.